New Heart Scan Review Finds Hidden Disease in "Low-Risk" Patients - 83% Show Signs of Treatable Heart Problems
BELLEVUE, WA / ACCESS Newswire / May 2, 2025 / A new study by Cardia Vision, LLC has revealed that a commonly used heart scan may be missing signs of early heart disease in many patients who appear 'low risk.' Using a more advanced imaging method, the research team discovered that 83% of patients had signs of treatable heart disease-even when traditional tests showed no cause for concern.Inside an Artery 1st frame-normal artery2nd-fatty plaque3rd-fibrous plaque4th-heart attack
The study focused on 100 patients who underwent both a calcium score test, which looks for hardened plaque in the arteries, and a more detailed scan called a coronary CT angiography (CCTA), which can detect softer, more dangerous plaque that doesn't show up on the more standard test.
Key findings include:
'This is potentially life-saving information,' said Dr. Kimberly Brockenbrough, Radiologist and CEO of Cardia Vision. 'Many people assume they're in the clear based on a single test, but we now know that dangerous plaque can be hiding undetected. CCTA gives us a clearer, more complete picture.'
Heart disease remains the leading cause of death in the U.S., and early detection is key. This research adds to a growing number of studies suggesting that advanced heart scans could play a crucial role in catching disease early and preventing serious events like heart attacks.
'It's time to rethink how we screen for heart disease,' added Dr. Brockenbrough. 'We have tools that can see the full picture-we just need to use them.'
About Cardia Vision
Cardia Vision is a preventative cardiovascular imaging center based in Bellevue, Washington, committed to diagnosing heart disease before a heart attack or sudden death.
Media Contact:
Dr. Kimberly Brockenbrough
425-998-8627
[email protected]
www.cardiavision.com
Cardia Vision, LLC
Bellevue, WA
Contact Information:
Kimberly Brockenbrough
CEO, Radiologist, and Founder
[email protected]
425-326-0031
SOURCE: Cardia Vision
press release
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
15 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Yahoo
a day ago
- Yahoo
How Will Quantum Technologies Transform the $9.8 Trillion Global Healthcare Sector?
A recent publication by quantum researcher Ali Karakuş draws the attention of the medical industry. BERLIN, DE / / June 5, 2025 / Quantum researcher Ali Karakuş has published a groundbreaking scientific paper that challenges the foundations of modern medicine and proposes a bold new perspective on health. The study introduces a next-generation medical model based on quantum sensors, ethical artificial intelligence, and resonance-based diagnostics-aiming to redefine our understanding of illness and healing. Global healthcare expenditures now exceed $9.8 trillion per year. Yet, despite this enormous financial investment, chronic illnesses, mental health disorders, and stress-related conditions are on the rise. According to Karakuş, the problem is not technological scarcity but the loss of harmonic alignment between humans, nature, and their own bodies. "We measure numbers but fail to listen to frequencies," says Karakuş. "We treat symptoms, yet overlook resonance breakdowns. The body must no longer be viewed as matter alone, but as a field of waves and energy." From Symptom Suppression to Resonance Restoration At the heart of the study is a quantum-sensor-based device in development that analyzes brainwaves, heart rate variability (HRV), vagus nerve activity, microbiome signals, and ethical resonance scores. All of this data is then processed by an ethical AI engine called Zulficore, producing a holistic and personalized feedback loop. A New Question for Medicine: "What's wrong?" or "What's out of tune?" The system designed by SlientWing integrates multiple disciplines including quantum biology, neuroscience, biomimetics, ecological AI, and ethics-based algorithms. The core question is shifting: Not "What disease do you have?" But "What frequency is disturbed? Which resonance with nature is lost?" Launch Timeline The beta version of the SlientWing device is expected to be field-tested by late 2026, with full-scale production and market launch scheduled for 2027. Manufacturing will be centered in Berlin and Thrace. Contact Information Ali Karakus Founderali@ SOURCE: Neuroscience & Quantum Researcher Ali Karakus View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Indianapolis Star
a day ago
- Indianapolis Star
New to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor Platforms
NEW YORK CITY, NEW YORK / ACCESS Newswire New to The Street, the nation's leading multi-platform financial news show, today announced it has signed a 12-part media partnership with NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company focused on life-saving therapies for patients with suicidal depression, PTSD, and chronic pain. The partnership will feature monthly televised interviews with NRx CEO Dr. Jonathan Javitt, providing updates from the front lines of biotech innovation. As part of the comprehensive campaign, New to The Street will also produce earned media placements on ABC, NBC, and CBS affiliates, a full suite of nationally aired TV commercials, and premium outdoor billboard exposure in Times Square and throughout the NYC Financial District. 'Our mission has always been to save lives with science,' said Jonathan Javitt, MD, MPH, Founder and CEO of NRx Pharmaceuticals. 'Partnering with New to The Street enables us to share the life-saving potential of NRX-101 and our broader pipeline with a national audience, at a pivotal moment in our regulatory and commercial path.' 'We are proud to bring NRX's critical work to our global audience,' said Vince Caruso, Co-Founder and CEO of New to The Street. 'This series will spotlight a company on the front lines of neuroscience and public health, and exemplifies our commitment to covering stories that matter-with scale, credibility, and impact.' The series begins airing later this month on Fox Business and Bloomberg Television as sponsored programming, reaching more than 245 million homes weekly across the U.S. and Middle East. Episodes will also stream on New to The Street's YouTube channel, which now exceeds 2.5 million subscribers, and be supported by billboard takeovers in Times Square and full media amplification through the NewsOut™ and platforms. About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders. Its lead investigational drug, NRX-101, has been granted FDA Breakthrough Therapy and Fast Track Designation for suicidal bipolar depression. The company is also pursuing accelerated approval for preservative-free IV ketamine (NRX-100) and advancing additional treatments for PTSD, chronic pain, and UTIs. Learn more at About New to The Street New to The Street is a leading branded content TV series that features innovative public and private companies on national television, including Fox Business and Bloomberg Television. With more than 2.52 million YouTube subscribers, a reach of 245 million TV households, and a powerful outdoor media footprint, the platform offers unmatched exposure across digital, television, and out-of-home channels. Learn more at SOURCE: New To The Street View the original press release on ACCESS Newswire
